News - Celgene

Filter

Current filters:

Celgene

Popular Filters

74 to 91 of 91 results

Study shows benefit of new maintenance therapy for multiple myeloma

14-05-2012

Multiple myeloma is a form of cancer where the plasma cells in the bone marrow grow out of control, causing…

BiotechnologyCelgenelenalidomideOncologyPharmaceuticalResearchRevlimid

US FDA warns on safety of Celgene's Revlimid; new Ph III trial results

11-05-2012

The US Food and Drug Administration this week issued a notification of an increased risk of second primary…

BiotechnologyCelgeneOncologyRegulationResearchRevlimid

Epizyme earns upfront $90 million in deal with Celgene; latter posts 17% sales hike

27-04-2012

Privately-held Epizyme and Celgene International Sarl, a subsidiary of USA-based Celgene Corp (Nasdaq:…

BiotechnologyCelgeneEpizymeFinancialLicensingOncologyPharmaceutical

Celgene makes $15 million investment in Acetylon

10-02-2012

US biotech Celgene (Nasdaq: CELG) will invest a total of $15 million in Acetylon Pharmaceuticals via…

Acetylon PharmaceuticalsBiotechnologyCelgeneFinancial

Celgene to buy Avila; posts strong 4th-qtr results

27-01-2012

USA-based Celgene (Nasdaq: CELG) yesterday revealed that it has entered into a definitive merger deal…

Avila TherapeuticsBiotechnologyCelgeneFinancialMergers & AcquisitionsOncologyPharmaceutical

5.6% annual growth forecast for multiple myeloma drug market to 2020

21-12-2011

Driven by further penetration of Celgene’s Revlimid (lenalidomide) into the first-line setting and…

CelgeneGlobalJanssen-CilagMarkets & MarketingOncologyPharmaceuticalRevlimidTakeda PharmaceuticalsVelcade

Celgene to drop Revlimid in CR prostate cancer following Ph III trial failure

23-11-2011

There was disappointment for blockbuster for multiple myeloma drug Revlimid (lenalidomide) when the Swiss…

BiotechnologyCelgeneOncologyPharmaceuticalResearchRevlimid

Celgene 3rd-qtr 2011 beats forecasts, boosted by Abraxis

27-10-2011

US biotech firm Celgene (Nasdaq: CELG) has reported non- generally accepted accounting principles (GAAP)…

BiotechnologyCelgeneFinancial

SMC backs Celgene’s Vidaza for rare blood and bone marrow cancers in Scotland

12-09-2011

The Scottish Medicines Consortium (SMC), the equivalent of the UK’s drug watchdog the National Institute…

BiotechnologyCelgeneEuropeOncologyPharmaceuticalPricingRegulationVidaza

Acceleron collaborates with Celgene on ACE-011 program in $242 million deal

05-08-2011

Expanding on a previous partnership, privately-held US drug developer Acceleron Pharma has entered into…

Acceleron PharmaCelgeneLicensingOncologyPharmaceuticalResearch

Celgene 2nd-qtr 2011 boosted by Revlimid and Vidaza

01-08-2011

US biotech firm Celgene (NasdaqGS: CELG) has presented strong second-quarter 2011 results, with adjusted…

BiotechnologyCelgeneFinancial

Celgene presents positive new data on cancer drug Revlimid in combination with Rituxan

19-06-2011

USA-headquartered Celgene (Nasdaq: CELG) presented strong data from a Phase II study, conducted by investigators…

CelgeneOncologyPharmaceuticalResearchRevlimidRituxan

74 to 91 of 91 results

Back to top